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1	trial	 0.05	 	 	
2	trials	*	 0.00125	*	 	 0.00008	(equivalent	to	
2	to	3	trials	at	p<0.05)	3	trials	 0.00003125	 	
4	trials	 0.00000078	 0.0000004	
(equivalent	to	4	to	5	
trials	at	p<0.05)	
	
5	trials	 0.0000000195	 	
*	Usual	regulatory	requirement	–	2	trials	at	P<0.05	OR	1	trial	at	P<0.00125	
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Table	2.	Class	of	recommendation	and	level	of	evidence	definitions	used	by	major	
guideline	bodies.	
		
Classes	of	
recommendations	
Definition	
Class	I	 Evidence	and/or	general	agreement	that	a	given	treatment	or	
procedure	is	beneficial,	useful,	effective	
Class	II	 Conflicting	evidence	and/or	a	divergence	of	opinion	about	the	
usefulness/efficacy	of	the	given	treatment	or	procedure	
						Class	IIa	 Weight	of	evidence	/	opinion	is	in	favour	of	usefulness/	efficacy	
						Class	IIb	 Usefulness/	efficacy	is	less	well	established	by	evidence/	
opinion	
Class	III	 Evidence	or	general	agreement	that	the	given	treatment	or	
procedure	is	not	useful/effective,	and	in	some	cases	may	be	
harmful	
	 	
Levels	of	Evidence	 Definition	
Level	of	evidence	A	 Data	derived	from	multiple	randomized	clinical	trials	or	meta-
analyses	
Level	of	evidence	B	 Data	derived	from	a	single	randomized	clinical	trial	or	large	
non-randomized	studies	
Level	of	evidence	C	 Consensus	of	opinion	of	the	experts	and/	or	small	studies,	
retrospective	studies,	registries	
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Table	3.	Starting	dose	and	dose	titration	for	sacubitril/valsartan	in	a	variety	of	patient	
populations	with	heart	failure	and	reduced	ejection	fraction	
	
Population	with	HF-REF	 Starting	dose	of	
sacubitril/valsartan*	
Up	titration	and	target	
dose	
No	patient	characteristics	requiring	
caution	or	dose	reduction		
100mg	twice	daily	
Up	titration	by	doubling	of	
dose	every	2-4	weeks	until	
a	target	dose	of	200mg	
twice	daily	is	reached	
Currently	only	able	to	tolerate	a	low	
or	submaximal	target	dose	of	ACE	
inhibitor	or	ARB**	
50mg	twice	daily	
No	ACE	inhibitor	or	ARB	in	the	past	 50mg	twice	daily	
eGFR	<30	ml/min/m2¶	 50mg	twice	daily	
Moderate	hepatic	impairment	
(Child	Pugh	Class	B)	
50mg	twice	daily	
Elderly	 50mg	twice	daily	
*	50mg	=	24mg	sacubitril/26mg	valsartan,	100mg	=	49mg	sacubitril/51mg	valsartan,	200mg	
=97	mg	sacubitril/103mg	valsartan	
**Target	doses	of	ACE	inhibitors	and	ARBs	are	as	follows:	ACE	inhibitors	–	captopril	50mg	
t.i.d	,	enalapril	10mg	b.i.d,	lisinopril		20mg	o.d.,	ramipril	5mg	b.i.d.,	trandolopril	4mg	o.d.	
ARBs	–	candesartan	32mg	o.d.,	losartan	150mg	o.d.,	valsartan	160mg	o.d.	
¶	The	European	Medicines	Agency	also	suggests	that	a	dose	of	50mg	(24mg/26mg)	can	be	
considered	if	eGFR	30-60	ml/min/m2	
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Figure	Legends	
	
Figure	1.	Pathways	blocked	by	ACE	inhibitors,	angiotensin	receptor	blockers	and	neprilysin	
inhibitors.		
	
Figure	2.	Effect	of	sacubitril/valsartan	on	the	rate	of	heart	failure	hospitalisations	as	a	
time	to	first	event	analysis	and	as	a	recurrent	event	analysis	of	total	hospitalisations	for	
heart	failure.	26	
	
Figure	3.	Effect	of	sacubitril/valsartan	on	the	rate	of	primary	endpoint	and	component	
and	all-cause	mortality	in	patients	randomised	in	the	PARADIGM-HF	trial	according	to	age	
group.27	P	for	interaction	for	cardiovascular	(CV)	death	or	heart	failure	(HF)	
hospitalisation=0.94,	for	CV	death	p	for	interaction=0.92,	for	HF	hospitalisation	p	for	
interaction=0.81	and	all-cause	death	p	for	interaction=0.99.		
	
Figure	4:	Stepwise	treatment	of	patients	with	symptomatic	(NYHA	II-IV)	heart	failure	with	
reduced	ejection	fraction.	Progressive	therapies	should	be	added	in	a	stepwise	fashion.	
Where	two	or	more	options	exist	on	a	step	the	most	appropriate	therapy	for	the	patient	
based	on	concomitant	medication	or	the	presence	of	other	patient	factors	should	be	
made.				
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